Latest & greatest articles for aids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aids

541. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.

A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. 7935655 1994 11 03 1994 11 03 2013 11 21 0028-4793 331 18 1994 Nov 03 The New England journal of medicine N. Engl. J. Med. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced (...) human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. 1181-7 Serious bacterial infections are common in children infected with the human immunodeficiency virus (HIV). Studies performed before zidovudine became standard therapy found that intravenous immune globulin decreases the number of serious bacterial infections in these children. We designed a multicenter study to evaluate the efficacy of intravenous immune globulin in children with advanced HIV infection who were receiving zidovudine

NEJM1994

542. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. 8479489 1993 05 27 1993 05 27 2015 11 19 0028-4793 328 21 1993 May 27 The New England journal of medicine N. Engl. J. Med. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. 1521-7 Both trimethoprim-sulfamethoxazole and pentamidine are effective as treatments for Pneumocystis carinii (...) pneumonia, but adverse effects frequently limit their use. Atovaquone (566C80) is a new hydroxynaphthoquinone with activity against P. carinii. We conducted a double-blind, multicenter study in patients with the acquired immunodeficiency syndrome and mild or moderately severe P. carinii pneumonia. They were randomly assigned to 21 days of orally administered treatment three times daily with either atovaquone (750 mg) or trimethoprim (320 mg) plus sulfamethoxazole (1600 mg). Of the 322 patients

NEJM1993

543. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. 8179648 1993 09 21 1993 09 21 2013 11 21 0028-4793 329 12 1993 Sep 16 The New England journal of medicine N. Engl. J. Med. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. 828-33 Disseminated Mycobacterium avium complex infection eventually develops in most patients with the acquired immunodeficiency syndrome (AIDS). This infection results (...) in substantial morbidity and reduces survival by about six months. We conducted two randomized, double-blind, multicenter trials of daily prophylactic treatment with either rifabutin (300 mg) or placebo. All the patients had AIDS and CD4 cell counts < or = 200 per cubic millimeter. The primary end point was M. avium complex bacteremia as assessed monthly by blood culture. The secondary end points were signs and symptoms associated with disseminated M. avium complex infection, adverse events, hospitalization

NEJM1993

544. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. 1353607 1992 09 02 1992 09 02 2013 11 21 0028-4793 327 9 1992 Aug 27 The New England journal of medicine N. Engl. J. Med. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. 581-7 Although zidovudine is effective in patients (...) with human immunodeficiency virus (HIV) infection, its efficacy may decline with prolonged use. Didanosine is another inhibitor of HIV reverse transcriptase. We evaluated the effectiveness of changing anti-HIV treatment from zidovudine to didanosine. This multicenter, double-blind study involved 913 patients who had tolerated zidovudine for at least 16 weeks. The patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex with less than or equal to 300 CD4 cells per cubic milliliter, or asymptomatic HIV

NEJM1992

545. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. 1360145 1992 12 29 1992 12 29 2015 11 19 0028-4793 327 26 1992 Dec 24 The New England journal of medicine N. Engl. J. Med. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia (...) in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. 1836-41 Primary prophylaxis against Pneumocystis carinii pneumonia (PCP) is recommended for patients with human immunodeficiency virus (HIV) infection if their CD4 cell counts are below 200 per cubic millimeter (0.2 x 10(9) per liter). Either aerosolized pentamidine or trimethoprim-sulfamethoxazole (co-trimoxazole) is commonly prescribed for prophylaxis, but the relative efficacy and toxicity of these agents

NEJM1992

546. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. 1448121 1992 12 29 1992 12 29 2015 11 19 0028-4793 327 26 1992 Dec 24 The New England journal of medicine N. Engl. J. Med. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia (...) in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. 1842-8 Pneumocystis carinii pneumonia (PCP) continues to be the most common index diagnosis in the acquired immunodeficiency syndrome (AIDS), but it is not clear which of several available agents is the most effective in preventing a recurrence of PCP. We conducted a comparative, open-label trial in 310 adults with AIDS who had recently recovered from an initial episode of PCP and had no treatment-limiting

NEJM1992

547. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group.

Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. 1346505 1992 03 09 1992 03 09 2013 11 21 0959-8138 304 6818 1992 Jan 04 BMJ (Clinical research ed.) BMJ Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. 13-7 To compare the efficacy and side effects of 400 mg, 800 mg, and 1200 mg zidovudine daily in patients with AIDS or (...) advanced HIV infection. Randomised, double blind, parallel group multicentre study. Hospital departments of infectious diseases and dermatology in Denmark, Sweden, Norway, Finland, and Iceland. 474 patients: 126 (27%) with AIDS; 248 (52%) with HIV related symptoms; 100 (21%) with low CD4+ cell counts. Zidovudine 400 mg (160 patients), 800 mg (158), or 1200 mg (156) daily. All patients received one capsule from each of three bottles four times daily. Survival; incidence of new HIV related events; CD4

BMJ1992 Full Text: Link to full Text with Trip Pro

548. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. 1727236 1992 01 10 1992 01 10 2013 11 21 0028-4793 326 2 1992 Jan 09 The New England journal of medicine N. Engl. J. Med. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. 83-9 Intravenous (...) amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS). Fluconazole, an oral triazole agent, represents a promising new approach to the treatment of cryptococcal disease. In a randomized multicenter trial, we compared intravenous amphotericin B with oral fluconazole as primary therapy for AIDS-associated acute cryptococcal meningitis. Eligible patients, in all of whom the diagnosis had been

NEJM1992

549. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. 1345799 1992 01 24 1992 01 24 2013 11 21 0028-4793 326 4 1992 Jan 23 The New England journal of medicine N. Engl. J. Med. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir (...) for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. 213-20 We performed a multicenter, randomized, unblinded clinical trial (the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial) designed to compare ganciclovir with foscarnet in the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS). Of 234 patients, 127 were randomly assigned to ganciclovir and 107 to foscarnet

NEJM1992

550. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.

A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. 1538722 1992 03 27 1992 03 27 2013 11 21 0028-4793 326 12 1992 Mar 19 The New England journal of medicine N. Engl. J. Med. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The (...) NIAID AIDS Clinical Trials Group and Mycoses Study Group. 793-8 After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse. We conducted a multicenter, randomized trial that compared fluconazole (200 mg per day given orally) with amphotericin B (1 mg per kilogram of body weight per week given intravenously) in patients with AIDS who had completed primary therapy

NEJM1992

551. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex.

Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. 1371323 1992 03 20 1992 03 20 2015 11 19 0140-6736 339 8791 1992 Feb 22 Lancet (London, England) Lancet Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. 453-6 To improve evaluation of new antiretroviral drugs in the acquired immunodeficiency syndrome (AIDS), sensitive biological markers (...) that accurately predict response to treatment are needed. Two possible markers are endogenous interferon (E-IFN), which is a cytokine involved in the pathophysiology of AIDS, and serum triglycerides (TG), which are raised in patients with AIDS, possibly reflecting enhanced cytokine activity. E-IFN, TG, body-mass index, CD4 count, and HIV p24 were measured in 19 patients (15 with AIDS, 4 with AIDS-related complex), who were part of the phase II licensing trial of zidovudine (ZDV). 10 received ZDV and 9

Lancet1992

552. Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS.

Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. 1346413 1992 03 03 1992 03 03 2015 06 16 0140-6736 339 8789 1992 Feb 08 Lancet (London, England) Lancet Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. 333-4 A double-blind, placebo-controlled trial was set up to compare clindamycin and pyrimethamine as prophylaxis (...) Z3614QOX8W Pyrimethamine AIM IM X Acquired Immunodeficiency Syndrome complications Adult Animals Clindamycin adverse effects Double-Blind Method Encephalitis complications prevention & control Female Humans Male Pyrimethamine therapeutic use Toxoplasma 1992 2 8 1992 2 8 0 1 1992 2 8 0 0 ppublish 1346413

Lancet1992

553. Effect of octreotide on refractory AIDS-associated diarrhea. A prospective, multicenter clinical trial.

Effect of octreotide on refractory AIDS-associated diarrhea. A prospective, multicenter clinical trial. Effect of octreotide on refractor... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1991 ) Volume: 115 , Issue: 9 , Pages: 705-710 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To determine the efficacy and safety of octreotide for treatment of refractory, profuse (...) diarrhea in patients with the acquired immunodeficiency syndrome (AIDS). DESIGN: A prospective, open-label study. SETTING: Inpatient metabolic units of four university medical centers. PATIENTS: Fifty-one patients infected with human immunodeficiency virus (HIV) who had uncontrolled diarrhea (greater than or equal to 500-mL liquid stool per day) despite treatment with maximally tolerable doses of antidiarrheal medications. INTERVENTION: After initial baseline studies, patients received octreotide, 50

Annals of Internal Medicine1991

554. Megestrol acetate in patients with AIDS-related cachexia.

Megestrol acetate in patients with AIDS-related cachexia. Megestrol acetate in patients wit... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1991 ) Volume: 48 , Issue: 2 , Pages: 165-166 Available from or Find this paper at: Abstract OBJECTIVES: To compare the effects of oral suspensions of megestrol acetate, 800 mg/d, and placebo on body weight in patients (...) with acquired immunodeficiency syndrome (AIDS)-related weight loss. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Outpatient community and university patient care setting. PATIENTS: Consecutive patients with AIDS who had substantial weight loss and anorexia were enrolled. Of 271 patients, 270 and 195 were evaluable for safety and efficacy, respectively. INTERVENTIONS: Patients were randomly assigned to receive placebo or megestrol acetate (100 mg, 400 mg, or 800 mg) daily for 12 weeks. MAIN OUTCOME MEASURES

Annals of Internal Medicine1991

555. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. 1649971 1991 08 26 1991 08 26 2013 11 21 0028-4793 325 8 1991 Aug 22 The New England journal of medicine N. Engl. J. Med. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. 551-5 Most (...) strains of herpes simplex virus that are resistant to acyclovir are susceptible in vitro to both foscarnet and vidarabine. We conducted a randomized trial to compare foscarnet with vidarabine in 14 patients with the acquired immunodeficiency syndrome (AIDS) and mucocutaneous herpetic lesions that had been unresponsive to intravenous therapy with acyclovir for a minimum of 10 days. The patients were randomly assigned to receive either foscarnet (40 mg per kilogram of body weight intravenously every 8

NEJM1991

556. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study.

Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. 1671884 1991 04 10 1991 04 10 2016 10 17 0098-7484 265 12 1991 Mar 27 JAMA JAMA Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. 1538-44 We randomized 389 symptomatic patients (...) with human immunodeficiency virus (HIV) infection to ditiocarb sodium (400 mg/m2 orally for 24 weeks) or a placebo. Patients were well balanced according to Centers for Disease Control (CDC) group, CD4+ cell number, and duration of disease prior to entry. Ten new acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections occurred in the treated patients and 21 in the controls. Reduction of new opportunistic infections in the ditiocarb group was significant in all patients (relative risk [RR], 0.44

JAMA1991

557. The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection

The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Office of Technology Assessment. The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection. Washington DC: U. S. Congress. Office of Technology Assessment (OTA) 1990: 160 Authors' objectives To examine evidence on the effectiveness of drug abuse treatment, to evaluate its potential role in reducing the spread of HIV, and to compare it to other approaches to HIV prevention among

Health Technology Assessment (HTA) Database.1990

558. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) [see comments]

Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) [see comments] Corticosteroids prevent early det... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1990 ) Volume: 113 , Issue: 1 , Pages: 14-20 Available from or Find this paper at: Abstract OBJECTIVE: To determine whether oral (...) corticosteroids can prevent early deterioration in patients with acquired immunodeficiency syndrome (AIDS)-related Pneumocystis carinii pneumonia. DESIGN: Prospective, double-blind, placebo-controlled, randomized trial. METHODS: Included patients were having their first P. carinii pneumonia episode, had no other known active pulmonary pathology, had no contraindications for corticosteroids, received no anti-P. carinii pneumonia medications for more than 48 hours, and had oxygen saturation by pulse oximetry

Annals of Internal Medicine1990

559. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. 1969115 1990 04 24 1990 04 24 2013 11 21 0028-4793 322 14 1990 Apr 05 The New England journal of medicine N. Engl. J. Med. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4 (...) -positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. 941-9 Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus (HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a randomized, double-blind trial in adults with asymptomatic HIV infection who had CD4+ cell counts of fewer than 500 per cubic millimeter on entry into the study. The subjects (92 percent

NEJM1990

560. Recombinant human erythropoietin for patients with AIDS treated with zidovudine.

Recombinant human erythropoietin for patients with AIDS treated with zidovudine. 2186273 1990 06 11 1990 06 11 2013 11 21 0028-4793 322 21 1990 May 24 The New England journal of medicine N. Engl. J. Med. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. 1488-93 Bone marrow suppression and anemia are frequent side effects of treatment of the acquired immunodeficiency syndrome (AIDS) with zidovudine (formerly azidothymidine [AZT]). We conducted a randomized, double (...) -blind, placebo-controlled clinical trial of recombinant human erythropoietin (100 U per kilogram of body weight thrice weekly by intravenous bolus) in 63 patients with AIDS treated with zidovudine (29 in the erythropoietin group and 34 in the placebo group). Reductions in the number of units of red cells transfused and the number of patients given transfusions per month became apparent in the second and third months of the trial. The reductions were observed in patients with endogenous

NEJM1990